Pre-operative radiochemotherapy of locally advanced rectal cancer

Table 1 Patient demography and disease charateristiscs at baseline

Parameter	RCS group	RS group
Male/female	12/3	21/6
Age (years): median (range)	56 (33-72)	58 (18-71)
Karnofsky performance status	70-90	70-90
Primary site
Middle	4	7
lower	11	20
Degree of differentiation
Well	1	2
Moderate	7	15
Poor	3	4
Not specified	4	6
TNM staging
T3N0M0	5	14
T3N1M0	0	3
T4N0M0	6	3
T4N1M0	4	5
T4N2M0	0	2

Table 2 The radical resectability, sphincter preservation, lower rectal cancer sphincter preservation, response and tumor down-stage rates in the two groups

Parameter	RCS group	RS group	P
Radical resectability rate	73.3%	37.0%	0.024
Sphincter preservation rate	26.6%	3.7%	0.028
Lower rectal cancer sphincter	27.3%	0.0%	0.014
preservation rate
Response rate	46.7%	18.5%	0.053
Tumor downstage rate	53.3%	33.3%	0.206

Table 3 The 3-year overall survival, disease free survival and local recurrent rates of the patients of two groups

Parameter	RCS group	RS group	P
3-year overall survival rate	66.7%	55.6%	0.485
3-year disease free survival rate	40.1%	33.2%	0.663
3-year local recurrent rate	26.7%	48.1%	0.174

Table 4 WHO modified scale for acute toxicity

Site	Grading (RCS group)					Grading (RS group)
	0	1	2	3	4	0	1	2	3	4
Hematologic:
Neutropenia	8	2	4	1	0	19	3	5	0	0
Non-hematologic:
Small bowl	4	3	7	3	0	6	9	10	2	0
Bladder	6	4	5	0	0	10	11	6	0	0
Skin	0	2	6	7	0	0	10	8	9	0